Autres langues Endonovo Therapeutics, Inc.

Actions

ENDV

US29272H3003

Marché Fermé - OTC Markets Autres places de cotation 21:42:11 13/05/2024			Varia. 5j.	Varia. 1 janv.
0,002 ^USD	+33,33%		-9,09%	-77,01%

2023	Endonovo Therapeutics, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 30 septembre 2023	CI
2023	Sofpulse® d'Endonovo Therapeutics, Inc. obtient l'approbation de la FDA de Taiwan	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc	28/03
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions	04/03
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/12
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million	04/12
Endonovo's SofPulse® Secures Taiwan FDA Approval	12/10/23
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	12/10/23
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22/08/23
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22/08/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update	08/08/23
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.	22/06/23
Endonovo Pending Agreement to Develop Telehealth Division	07/06/23
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	07/06/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
Endonovo Launches SofPulse® into the Veterans Administration	02/05/23
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	02/05/23
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies	25/04/23
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	25/04/23
ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	17/04/23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Endonovo Therapeutics, Inc.

Actions

ENDV

US29272H3003

Autres langues

Filtres